Navigation Links
Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001

HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for cancer patients. The results of a successfully completed clinical study will be presented to an international audience at the Annual Conference of the American Society for Clinical Oncology (ASCO) in Chicago, USA. ASCO is the most important professional organization of cancer specialists world-wide.

The active substance VPM4001, an immunotherapeutic for cancer treatment, has reached an important stage of development: A clinical phase I/II study with 30 patients successfully completed in 2006 showed that 73 % of patients suffering from advanced, hormone-resistant prostate carcinoma responded positively to the VPM4001 therapy. The primary study parameter, the PSA doubling time, was increased from 63 days to 114 days on average. This promising result has a high statistical significance (p=0.0035). VPM4001 also showed an excellent tolerability profile. The study was carried out at the Institute for Experimental Oncology (Prof. Dr. med. B. Gansbacher) and at the Clinic for Urology (Prof. Dr. med. R. Hartung) of Munich Technical University.

The new vaccine will support the immune system to fight cancer. Based on the promising results, a panel of international experts from the USA, Germany and the Netherlands has recommended the continuation of clinical development of the vaccine as fast as possible. Prostate cancer is the most frequent type of tumor affecting male patients aged 50+ and also the third most frequent cause of death resulting from cancer disease. Each year approx. 420,000 people in Europe and in the USA are affected by prostate cancer. The life-time risk of becoming affected by prostate cancer is 1:6.

VPM4001 is an ideal example for the development of innovative vaccines initiated by VPM. This has lead to the development project being int
'"/>




Page: 1 2

Related medicine technology :

1. Choosing Lab Quality Management Software
2. Optimizing Quality Control Data Management
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
6. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
Post Your Comments:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... BOTHELL, Wash. , May 22, 2015  BioLife Solutions, ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues ("BioLife" or the "Company"), ... 2015 Marcum MicroCap Conference. The Company is ... on Wednesday, May 27, 2015 at the Grand Hyatt Hotel ...
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... protection, repair and regeneration, today announced that J.J. ... to present a corporate overview at two upcoming investor ... the SeeThruEquity 4 th Annual Microcap Conference on ... City at 11:00 am EDT.  A webcast ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... BOTHELL, Wash., Jan. 8 Nastech Pharmaceutical,Company Inc. ... enrollment for its,Phase 2 clinical trial of PYY3-36 ... obese patients at multiple clinical sites in the ... study. The,study is designed to evaluate three different ...
... Logix today announced positive,results in the Company,s Phase ... double-blind, placebo-controlled crossover,Phase 2a study in 60 patients ... reductions in blood pressure,and was well tolerated. The ... effect on blood pressure in patients of repeat ...
Cached Medicine Technology:Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 2Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity 3Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension 2Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension 3
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... will allow them to take pressure measurements in patients’ ... function. The doctor usually orders it if they have ... bladder (OAB). , Women’s Excellence in Bladder ... problems with unwanted urinary leakage or problems with overall ...
(Date:5/24/2015)... Indiana (PRWEB) May 24, 2015 Indiana ... service provider announces Midwest Telecom of America, Inc. (MTA) ... , According to Cory Childs, IFN Enterprise Sales Manager, ... service providers. “IFN’s fiber transport provides MTA with ... Center to their Tier 1 Internet and voice carriers ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... May 23, 2015 Manufacturers are now required ... Factor (HSPF) of 8.2. Experts in the field agree that ... consumers. , The HSPF score is what miles per gallon ... efficient the unit. Although the minimum HSPF score has been ... with an HSPF score north of 12. Indeed, the regulation ...
(Date:5/22/2015)... 2015 The world is at ... are intersecting to create new opportunities for leadership ... speaker at WesternU's 34th annual Commencement Exercises said ... Newsom, a former San Francisco mayor and likely ... the graduation ceremony for WesternU's colleges of Allied ...
Breaking Medicine News(10 mins):Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3
... can quickly become a potent cancer promoter in adult mice ... Cancer Center, causing white blood cells to become cancerous spontaneously. ... Research, the researchers detail how a gene called Dlx5 works ... mice. The protein that Dlx5 encodes could be a target ...
... Take Charge of Your Health - A Self-Care Initiative and the ... ... 27 Blue Cross of,California,s Self-Care Initiative and Member Health Index ... Cross and Blue Shield,Association, BlueWorks recognizes the innovative ways Blue Cross ...
... Acuitec,s Vigilance has been,awarded the 2008 ... for Clinical Records -- Inpatient. The Vigilance ... Anesthesia at Vanderbilt University,Medical Center, enables clinicians ... the physician to customize built-in,intelligent alerts based ...
... 1950s for causing birth defects, is now showing promise ... recurrent ovarian cancer, according to a study led by ... Jr., M.D., principal investigator for the multicenter, randomized Phase ... research study in the current issue of the journal ...
... of dollars spent on food safety research over the last ... were higher in 2007 than in 2006, according to researchers ... coli O157:H7 has been linked to foodborne illnesses in humans ... studying the effects of a novel vaccine technology to make ...
... be encouraged to get inoculated , , WEDNESDAY, Feb. 27 ... all children 6 months to 18 years of age ... that children 6 months to 5 years of age ... Centers for Disease Control and Prevention,s Advisory Committee on ...
Cached Medicine News:Health News:Inverted DNA turns quiet developmental gene into a potent driver of t-cell lymphoma 2Health News:Blue Cross of California Honored with Two BlueWorks(R) Awards 2Health News:Blue Cross of California Honored with Two BlueWorks(R) Awards 3Health News:Blue Cross of California Honored with Two BlueWorks(R) Awards 4Health News:Acuitec's Vigilance Product Wins Microsoft Award as Most Innovative Product for 2008 2Health News:U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer 2Health News:Researchers collaborate to find new vaccine technology decreases E. coli in beef cattle 2Health News:CDC Panel Urges Extending Flu Vaccine Coverage for Kids 2Health News:CDC Panel Urges Extending Flu Vaccine Coverage for Kids 3
... Products are constructed of a ... MEROCEL polyvinyl acetal sponge. Each ... beneficial to both surgeon and ... yet firm enough to gently ...
... Ophthalmic Products are constructed of ... lint-free MEROCEL polyvinyl acetal sponge. ... be beneficial to both surgeon ... and yet firm enough to ...
...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Medicine Products: